Ding ZY, Li GX, Chen L, et al. - Researchers undertook this large retrospective cohort analysis to analyze evolution as well as the clinical significance of abnormal liver chemistries and the influence of hepatitis B infection on the outcomes in patients suffering from COVID-19 (coronavirus disease 2019). Participants were 2,073 COVID-19 cases having definite outcomes in Wuhan, China. Of these, 1,282 (61.8%) were found to have abnormal liver chemistries during hospitalization, and 297 (14.3%) suffered a liver injury. There was a rise in the mean levels of AST (aspartate aminotransferase) and D-Bil (direct bilirubin) early following symptom onset in deceased patients and these levels displayed disparity vs that in discharged patients throughout the clinical course of the disease. The risk of COVID-19-related poor outcomes was not increased by hepatitis B virus infection in patients. Findings revealed that COVID-19 mortality was independently predicted by abnormal AST and D-Bil levels at admission. Thus, it is crucial to monitor liver chemistries, especially AST and D-Bil concentrations, in hospitalized patients with COVID-19.